Onasemnogene abeparvovec commonly linked to hepatotoxicity
27 Feb 2021
Hepatotoxicity is common after treatment with onasemnogene abeparvovec for spinal muscular atrophy, a recent study has found. Clinicians should anticipate and be ready to manage such adverse events, and be aware of any potential underlying conditions that could aggravate them.
Indications/Uses : In combination w/ fulvestrant for postmenopausal women & men w/ hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after endocrine-based regimen.
Indications/Uses : Active booster immunization for prevention of tetanus, diphtheria & pertussis (whooping cough) in persons ≥4 yr. Passive protection against pertussis in early infancy following maternal immunization during pregnancy. Concomitant w/ inactivated poliomyelitis vaccine as alternative for 5th dose of tetanus, diphtheria & acellular pertussis vaccine (DTaP) in childn 4-6 yr.